Safi Shahda, MD

Dr. Shahda on BBI-608 With Gemcitabine and Nab-Paclitaxel in Patients with mPDAC

January 23rd 2016

Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.